

## APC anti-mouse CD3ε Antibody

<b>Catalog# / Size</b>	100311 / 25 µg 100312 / 100 µg
<b>Clone</b>	145-2C11
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	CD3ε, T3, CD3
<b>Isotype</b>	Armenian Hamster IgG
<b>Description</b>	CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Armenian Hamster
<b>Immunogen</b>	H-2K <sup>b</sup> -specific mouse cytotoxic T lymphocyte clone BM10-37
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The CD3ε antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	Clone 145-2C11 is useful for <i>in vitro</i> blocking of target-specific CTL-mediated cell lysis <sup>1</sup> , as well as T cell activation assays, inducing proliferation and cytokine production <sup>1,2,7,12,16</sup> . It also induces apoptosis in immature thymocytes <sup>3,2</sup> , and <i>in vivo</i> T cell depletion <sup>8-10</sup> . Additional reported applications (for relevant formats of this clone) include: immunoprecipitation <sup>1</sup> , immunohistochemical staining <sup>14,15</sup> of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting <sup>4</sup> , complement-mediated cytotoxicity <sup>6</sup> , <i>in vitro</i> and <i>in vivo</i> stimulation of T cells <sup>1,2,7,12,16</sup> , immunofluorescent staining <sup>5</sup> , and <i>in vivo</i> T cell depletion <sup>8-10</sup> . The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells <sup>11</sup> . Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For <i>in vivo</i> studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Leo O, <i>et al.</i> 1987. <i>P. Natl. Acad. Sci. USA</i> 84:1374. (IP, Activ, Block)</li> <li>2. Kruisbeek AM, <i>et al.</i> 1991. <i>In Current Protocols in Immunology</i>. 3.12.1. (Activ)</li> <li>3. Duke RC, <i>et al.</i> 1995. <i>Current Protocols in Immunology</i>. 3.17.1.</li> <li>4. Salvadori S, <i>et al.</i> 1994. <i>J. Immunol.</i> 153:5176. (WB)</li> </ol>
<b>(PubMed link indicates BioLegend citation)</b>	

5. Payer E, *et al.* 1991. *J. Immunol.* 146:2536. (IF)
6. Jacobs H, *et al.* 1994. *Eur. J. Immunol.* 24:934. (CMCD)
7. Vossen ACTM, *et al.* 1995. *Eur. J. Immunol.* 25:1492. (Activ)
8. Henrickson M, *et al.* 1995. *Transplantation* 60:828. (Deplete)
9. Kinnaert P, *et al.* 1996. *Transpl. Int.* 9:386. (Deplete)
10. Han WR, *et al.* 1999. *Transpl. Immunol.* 7:207. (Deplete)
11. Miescher GC, *et al.* 1989. *Immunol. Lett.* 23:113. (Block)
12. Terrazas LI, *et al.* 2005. *Intl. J. Parasitology.* 35:1349. (Activ)
13. Ko SY, *et al.* 2005. *J. Immunol.* 175:3309.
14. Podd BS, *et al.* 2006. *J. Immunol.* 176:6532. (IHC-F)
15. Tilley SL, *et al.* 2007. *J. Immunol.* 178:3208. (IHC-F)
16. Wang W, *et al.* 2007. *J. Immunol.* 178:4885. (Activ)
17. Xiao S, *et al.* 2007. *J. Exp. Med.* 204:1691.
18. Chappaz S, *et al.* 2007. *Blood* doi:10.1182/blood-2007-02-074245. (FC) [PubMed](#).
19. Curtsinger JM, *et al.* 2005. *J. Immunol.* 175:4392. [PubMed](#)
20. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
21. Kenna TJ, *et al.* 2008. *Blood* 111:2091.
22. Perchonock CE, *et al.* 2007. *J. Immunol.* 179:1768. [PubMed](#)
23. Perchonock GE, *et al.* 2006. *Mol. Cell. Biol.* 26:6005. [PubMed](#)
24. Kanaya T, *et al.* 2008. *Am. J. Physiol. Gastrointest. Liver Physiol.* 295:G273. [PubMed](#)
25. de Koning BA, *et al.* 2006. *Int. Immunol.* 18:941. [PubMed](#)
26. Schulteis RD, *et al.* 2008. *Blood* 295:G273. [PubMed](#)
27. Qi Q, *et al.* 2009. *Blood* 114:564. [PubMed](#)
28. Helmersson S, *et al.* 2013. *Am J Pathol.* 9440:123. [PubMed](#)
29. Wu S, *et al.* 2014. *Clin Vaccine Immunol.* 21:156. [PubMed](#)
30. Yan J, *et al.* 2014. *Vaccine.* 32:2833. [PubMed](#)
31. Guiterrez DA, *et al.* 2014. *Diabetes.* 63:3827. [PubMed](#)
32. Shi YF, *et al.* 1991. *J Immunol.* 146:3340. (Apop)

## Product Citations

1. Barrett N, *et al.* 2016. *Cell Rep.* 16: 1039-1054. [PubMed](#)
2. Glasner A, *et al.* 2017. *Sci Rep.* 10.1038/s41598-017-12998-w. [PubMed](#)
3. Chan LC, *et al.* 2019. *J Clin Invest.* 129:3324. [PubMed](#)
4. Dong MB, *et al.* 2020. *Cell.* 178(5):1189-1204.e23. [PubMed](#)
5. Wang Q, *et al.* 2020. *Radiat Environ Biophys.* 59:89. [PubMed](#)
6. Ferrari de Andrade L, *et al.* 2020. *Cancer Immunol Res.* 0.867361111. [PubMed](#)
7. Pennock N, *et al.* 2014. *Proc Natl Acad Sci U S A.* 111:16472. [PubMed](#)
8. Ajina R, *et al.* 2019. *Oncoimmunology.* 8:e1577127. [PubMed](#)
9. Yamaguchi S, *et al.* 2021. *Eur J Immunol.* 51:2306. [PubMed](#)
10. Yang Z, *et al.* 2022. *J Immunother Cancer.* 10: [PubMed](#)
11. Fujimori S, *et al.* 2022. *Elife.* 11: [PubMed](#)
12. Ma J, *et al.* 2020. *Adv Sci (Weinh).* 7:2000609. [PubMed](#)
13. Symeonidou V, *et al.* 2021. *Cell Rep.* 37:109900. [PubMed](#)
14. Okamoto M, *et al.* 2014. *J Immunol.* 192:2770. [PubMed](#)
15. Nakamura M, *et al.* 2015. *J Immunol.* 194:243. [PubMed](#)
16. Altshuler A, *et al.* 2021. *Cell Stem Cell.* 28(7):1248-1261.e8. [PubMed](#)
17. Delacher M, *et al.* 2021. *Immunity.* 54(4):702-720.e17. [PubMed](#)
18. Roufaiel M, *et al.* 2016. *Nat Immunol.* 10.1038/ni.3564. [PubMed](#)
19. Ku M, *et al.* 2016. *Mol Cancer Ther.* 15: 1975 - 1987. [PubMed](#)
20. Agelidis A, *et al.* 2019. *Front Immunol.* 10:500. [PubMed](#)
21. Yang X, *et al.* 2020. *Blood Sci.* 2:89. [PubMed](#)
22. Volpedo G, *et al.* 2022. *NPJ Vaccines.* 7:32. [PubMed](#)
23. Wang Y, *et al.* 2016. *Sci Rep.* 6:31881. [PubMed](#)
24. Mukherjee D, *et al.* 2022. *Nat Commun.* 13:3747. [PubMed](#)
25. Yang W, *et al.* 2020. *Mucosal Immunol.* 13:788. [PubMed](#)
26. Jung BG, *et al.* 2022. *PLoS Pathog.* 18:e1010454. [PubMed](#)
27. Haugh KA, *et al.* 2021. *eLife.* 0.4166666666666667. [PubMed](#)
28. Sato K, *et al.* 2015. *PLoS One.* 10: 0138291. [PubMed](#)
29. Lercher A, *et al.* 2019. *Immunity.* 51:1074. [PubMed](#)
30. Gao JL, *et al.* 2019. *JCI Insight.* 4:e132140. [PubMed](#)
31. Gorczynski RM, *et al.* 2017. *Immunology.* 150:418. [PubMed](#)
32. Wang J, *et al.* 2018. *Front Immunol.* 9:371. [PubMed](#)
33. Zhou H, *et al.* 2022. *EMBO Rep.* 23:e53475. [PubMed](#)
34. Wan W, *et al.* 2015. *Cardiovasc Res.* 106:478. [PubMed](#)
35. Montel-Hagen A, *et al.* 2020. *Cell Rep.* 33:108320. [PubMed](#)
36. Fujita K, *et al.* 2019. *Proc Natl Acad Sci U S A.* 116:14714. [PubMed](#)
37. Dane EL, *et al.* 2022. *Nat Mater.* 21:710. [PubMed](#)
38. Leiva M, *et al.* 2016. *Nat Commun.* 7:10222. [PubMed](#)
39. Holvoet B, *et al.* 2015. *Stem Cell Reports.* 5: 1183-1195. [PubMed](#)
40. Burrack K, *et al.* 2015. *PLoS Pathog.* 11: e1005191. [PubMed](#)
41. Lopez DA, *et al.* 2022. *Cell Rep.* 41:111677. [PubMed](#)
42. Aebischer D, *et al.* 2014. *PLoS One.* 9:99297. [PubMed](#)
43. Codina A, *et al.* 2019. *Cell Syst.* 8:136. [PubMed](#)
44. Xu H, *et al.* 2020. *Immunity.* 51(4):696-708.e9. [PubMed](#)
45. Dong S, *et al.* 2021. *Nature.* 591:117. [PubMed](#)
46. Ghandhi SA, *et al.* 2022. *Sci Rep.* 12:14124. [PubMed](#)
47. Mansell E, *et al.* 2020. *Cell Stem Cell.* [PubMed](#)
48. Ringel AE, *et al.* 2020. *Cell.* 183(7):1848-1866.e26. [PubMed](#)
49. Ito C, *et al.* 2015. *PLoS One.* 10: e0140808. [PubMed](#)

50. Siggs O, *et al.* 2015. Proc Natl Acad Sci U S A. 112: E5706 - E5714. [PubMed](#)
51. Burrack K, *et al.* 2015. J Immunol. 194:678. [PubMed](#)
52. Parhi L, *et al.* 2020. Nat Commun. 2.721527778. [PubMed](#)
53. Hum NR, *et al.* 2022. Front Oncol. 12:928474. [PubMed](#)
54. Luck H, *et al.* 2015. Cell Metab. 21 527 . [PubMed](#)
55. Nosh S, *et al.* 2020. Int J Mol Sci. 21:00. [PubMed](#)
56. Zhang H, *et al.* 2019. Mol Cell. 76:110. [PubMed](#)
57. Oksenysh V, *et al.* 2021. Biomolecules. 12:. [PubMed](#)
58. Mittal A, *et al.* 2021. Sci Rep. 11:10731. [PubMed](#)
59. Gu X, *et al.* 2022. Vaccines (Basel). 10:. [PubMed](#)
60. Liu B, *et al.* 2022. Mol Med Rep. 26:. [PubMed](#)
61. Uto T, *et al.* 2016. Nat Commun. 7: 11273. [PubMed](#)
62. Rovira-Clavé X, *et al.* 2016. J Leukoc Biol. 99: 143 - 152. [PubMed](#)
63. XS R, *et al.* 2015. Diabetes. 64 90. [PubMed](#)
64. Liu Z, *et al.* 2020. Cell. 178(6):1509-1525.e19.. [PubMed](#)
65. Ghandhi SA, *et al.* 2019. Sci Rep. 9:19434. [PubMed](#)
66. Xia P *et al.* 2018. Immunity. 48(4):688-701 . [PubMed](#)
67. Liu S, *et al.* 2018. Front Immunol. 29:208. [PubMed](#)
68. Sun Y, *et al.* 2022. Mol Ther Oncolytics. 25:160. [PubMed](#)
69. Huang J, *et al.* 2014. J Immunol. 192:1972. [PubMed](#)
70. Gubin MM, *et al.* 2018. Cell. 175:1014. [PubMed](#)
71. Zhang X, *et al.* 2021. Mol Cancer Res. 19:1076. [PubMed](#)
72. Li D, *et al.* 2022. Emerg Microbes Infect. 11:2248. [PubMed](#)
73. Liu Y, *et al.* 2022. Am J Transl Res. 14:6856. [PubMed](#)
74. Nahrendorf W, *et al.* 2021. eLife. 10:00. [PubMed](#)
75. Gong N, *et al.* 2020. Nat Nanotechnol. 1.35625. [PubMed](#)
76. Metidji A *et al.* 2018. Immunity. 49(2):353-362 . [PubMed](#)
77. Zhang CR, *et al.* 2022. Blood Cancer Discov. 3:220. [PubMed](#)
78. Zhang Q, *et al.* 2022. JCI Insight. 7:. [PubMed](#)
79. Wang Y, *et al.* 2021. Nat Commun. 12:4964. [PubMed](#)
80. Wang W, *et al.* 2021. J Am Heart Assoc. 10:e019142. [PubMed](#)
81. Berghoff SA, *et al.* 2021. Nat Neurosci. 24:47. [PubMed](#)
82. Shibuya M, *et al.* 2021. iScience. 24:103131. [PubMed](#)
83. Liang Q, *et al.* 2020. Front Microbiol. 11:571847. [PubMed](#)
84. Miura N, *et al.* 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. [PubMed](#)
85. Onai N, *et al.* 2020. Int J Mol Sci. :22. [PubMed](#)
86. Celik H, *et al.* 2018. Cancer Cell. 34:741. [PubMed](#)
87. Kang YH, *et al.* 2019. Nat Commun. 10:912. [PubMed](#)
88. Castañeda-Zegarra S, *et al.* 2019. Biomolecules. 0.929166667. [PubMed](#)
89. Casanova-Acebes M, *et al.* 2018. J Exp Med. 215:2778. [PubMed](#)
90. Omatsu Y, *et al.* 2022. Nat Commun. 13:2654. [PubMed](#)
91. Jing Y, *et al.* 2021. Front Immunol. 12:651860. [PubMed](#)
92. Bergquist M, *et al.* 2014. J Infect. 69:113. [PubMed](#)
93. McCauley ME, *et al.* 2020. Nature. 585(7823):96-101. [PubMed](#)
94. Ulaganathan VK, *et al.* 2020. Sci Rep. 10:8453. [PubMed](#)
95. Dükling T, *et al.* 2022. Sci Adv. 8:eabo7639. [PubMed](#)
96. Shaikh H, *et al.* 2021. Front Immunol. 12:689896. [PubMed](#)
97. Bajaña S, *et al.* 2022. iScience. 25:103732. [PubMed](#)
98. Koide S, *et al.* 2022. iScience. 25:103603. [PubMed](#)
99. Zhu E, *et al.* 2014. J Immunol. 192:5599. [PubMed](#)
100. Yang X, *et al.* 2021. Bioact Mater. 3150:6. [PubMed](#)
101. Rousso-Noori L, *et al.* 2021. Nat Commun. 12:3615. [PubMed](#)
102. Zhou S, *et al.* 2021. Adv Funct Mater. 31:. [PubMed](#)
103. Sato Y, *et al.* 2022. Front Mol Biosci. 9:1040237. [PubMed](#)
104. Bonavita E, *et al.* 2020. Immunity. 1215:53. [PubMed](#)
105. Pelly V, *et al.* 2016. Mucosal Immunol. 10.1038/mi.2016.4. [PubMed](#)
106. Arensman MD, *et al.* 2020. Oncoimmunology. 9:1800162. [PubMed](#)
107. Parks CA, *et al.* 2019. Proc Natl Acad Sci U S A. 116:3136. [PubMed](#)
108. Chryplewicz A, *et al.* 2022. Cancer Cell. 40:1111. [PubMed](#)
109. Stephens HM, *et al.* 2022. Methods Mol Biol. 2478:727. [PubMed](#)
110. Sun Y, *et al.* 2022. iScience. 25:104846. [PubMed](#)
111. Xu G, *et al.* 2015. Free Radic Biol Med. 87: 15-25. [PubMed](#)
112. Cruz F, *et al.* 2016. Stem Cells Trans Med. 5: 488-499. [PubMed](#)
113. Huang X, *et al.* 2021. Immunity. . [PubMed](#)
114. Timilshina M, *et al.* 2020. Cell Reports. 27(10):2948-2961.e7.. [PubMed](#)
115. Radulovic V, *et al.* 2020. Cell Reports. 27(10):2826-2836.e5.. [PubMed](#)
116. Liu Z, *et al.* 2020. STAR Protoc. 1:100029. [PubMed](#)
117. Dourcy M, *et al.* 2020. Mucosal Immunol. 13:799. [PubMed](#)
118. Harvey RE *et al.* 2017. Endocrinology. 158(7):2179-2189 . [PubMed](#)
119. Campisi L, *et al.* 2016. Nat Immunol. 10.1038/ni.3512. [PubMed](#)
120. Yu YR, *et al.* 2020. STAR Protocols. 11(3):e0150606. [PubMed](#)
121. Omenetti S, *et al.* 2019. Immunity. 51:77. [PubMed](#)
122. Tong Y, *et al.* 2018. EBioMedicine. 39:132. [PubMed](#)
123. Shi GN, *et al.* 2021. Ther Adv Med Oncol. 13:1758835920987056. [PubMed](#)

RRID

AB\_312676 (BioLegend Cat. No. 100311)  
 AB\_312677 (BioLegend Cat. No. 100312)

## Antigen Details

---

<b>Structure</b>	Ig superfamily, forms CD3/TCR complex with CD3 $\delta$ , $\gamma$ and $\zeta$ subunits and TCR ( $\alpha/\beta$ and $\gamma/\delta$ ), 20 kD
<b>Distribution</b>	Thymocytes (differentiation dependent), mature T cells, NK-T cells
<b>Function</b>	TCR signal transduction, T cell activation, antigen recognition
<b>Ligand/Receptor</b>	Peptide antigen/MHC-complex
<b>Cell Type</b>	NKT cells, T cells, Thymocytes, Tregs
<b>Biology Area</b>	Immunology
<b>Molecular Family</b>	CD Molecules, TCRs
<b>Antigen References</b>	1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Davis MM. 1990. <i>Annu. Rev. Biochem.</i> 59:475. 3. Weiss A, <i>et al.</i> 1994. <i>Cell</i> 76:263.
<b>Gene ID</b>	<a href="#">12501</a>

## Related Protocols

---

[Cell Surface Flow Cytometry Staining Protocol](#)


## Other Formats

---

APC anti-mouse CD3 $\epsilon$ , Biotin anti-mouse CD3 $\epsilon$ , FITC anti-mouse CD3 $\epsilon$ , PE anti-mouse CD3 $\epsilon$ , PE/Cyanine5 anti-mouse CD3 $\epsilon$ , Purified anti-mouse CD3 $\epsilon$ , PE/Cyanine7 anti-mouse CD3 $\epsilon$ , Alexa Fluor® 488 anti-mouse CD3 $\epsilon$ , Alexa Fluor® 647 anti-mouse CD3 $\epsilon$ , PerCP anti-mouse CD3 $\epsilon$ , PerCP/Cyanine5.5 anti-mouse CD3 $\epsilon$ , Purified anti-mouse CD3 $\epsilon$  (Maxpar® Ready), APC/Cyanine7 anti-mouse CD3 $\epsilon$ , Pacific Blue™ anti-mouse CD3 $\epsilon$ , Brilliant Violet 421™ anti-mouse CD3 $\epsilon$ , Ultra-LEAF™ Purified anti-mouse CD3 $\epsilon$ , PE/Dazzle™ 594 anti-mouse CD3 $\epsilon$ , Brilliant Violet 510™ anti-mouse CD3 $\epsilon$ , Brilliant Violet 605™ anti-mouse CD3 $\epsilon$ , Brilliant Violet 711™ anti-mouse CD3 $\epsilon$ , Brilliant Violet 785™ anti-mouse CD3 $\epsilon$ , APC/Fire™ 750 anti-mouse CD3 $\epsilon$ , GolnVivo™ Purified anti-mouse CD3 $\epsilon$ , Spark YG™ 593 anti-mouse CD3

## Product Data

---



C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) APC (filled histogram) or Armenian hamster IgG APC isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

